Clinical Trials
117 trialsCombining Topical Imiquimod With Local Radiotherapy for Treatment of Mycosis Fungoides
Northwestern University
Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer
M.D. Anderson Cancer Center
Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma
Mayo Clinic
Topical Imiquimod Treatment of Oral Dysplasia
University of Southern California
Immunotherapy for Recurrent Ependymomas in Children Using Tumor Antigen Peptides With Imiquimod
University of Pittsburgh
A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)
UroGen Pharma Ltd.
SONIB
Melanoma Institute Australia
INTERCEPT-H3
German Cancer Research Center
Imiquimod, Fluorouracil, or Observation in Treating HIV-Positive Patients With High-Grade Anal Squamous Skin Lesions
AIDS Malignancy Consortium
Topical Fluorouracil and Imiquimod in Treating Patients With High-Grade Cervical Intraepithelial Neoplasia
National Cancer Institute (NCI)
Risk of Squamous Cell Carcinoma on Skin Areas Treated With Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5%
LEO Pharma
Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme
Stemline Therapeutics, Inc.
Neoadjuvant Imiquimod Immunotherapy for Oral Cancer
Medical University of South Carolina
HPV-VIM
Baylor College of Medicine
Comparing Immune Responses to Topical Imiquimod
University of California, Davis
ANCHOR
AIDS Malignancy Consortium
Dendritic Cell Vaccine for Children and Adults With Sarcoma
University of Miami
RADICAL
Melanoma and Skin Cancer Trials Limited
Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With Granulocyte Macrophage Colony-stimulating Factor (GM-CSF) and Imiquimod
Beth Israel Deaconess Medical Center
Treatment of High-Grade Pre-Neoplastic Cervical Lesions (CIN 2/3)
Yale University
REDT-BCC
Maastricht University Medical Center
CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in Children and Young Adults
OX2 Therapeutics
Patient-individualized Peptide Vaccination Based on Tumor-specific Mutations in Children and Young Adults With Primary/Relapsed ALL
University Children's Hospital Tuebingen
PRedICT-TOPIC
Catharina Ziekenhuis Eindhoven
Vaccine Therapy With or Without Imiquimod in Treating Patients With Grade 3 Cervical Intraepithelial Neoplasia
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)
Inovio Pharmaceuticals
Treatment of Nodular Basal Cell Carcinoma (BCC) With Imiquimod 5% Cream After Curettage
Wake Forest University Health Sciences
PACKS
Zealand University Hospital
iVAC-CLL01: Patient-individualized Peptide Vaccination After First Line Therapy of CLL
University Hospital Tuebingen
NY-ESO-1 Protein Vaccine With Imiquimod in Melanoma (Adjuvant Setting)
Ludwig Institute for Cancer Research
Dendritic Cell (DC) Vaccine for Malignant Glioma and Glioblastoma
University of Miami
Aldara for the Treatment of Large and/or Multiple sBCC
Viatris Inc.
A Study to Evaluate Effectiveness of Imiquimod 5% Cream in Superficial Basal Cell Carcinoma
Viatris Inc.
A Study to Follow up Recurrence Rates of Actinic Keratoses One Year After Completion of Study 1487-IMIQ
Viatris Inc.
A Study to Evaluate the Effectiveness and Safety of Multiple Applications of Imiquimod 5% Cream for the Treatment of Actinic Keratoses in Organ Transplant Recipients
Viatris Inc.
Study of Imiquimod Cream Prior to Ablative Therapy in External Ano-Genital Warts
Viatris Inc.
Evaluation of Two Different Non-invasive Techniques to Monitor the Clearance of Actinic Keratosis Lesions
Viatris Inc.
Imiquimod 5% Cream in the Treatment of External Genital or Perianal Warts in HIV+ Patients
Viatris Inc.
LEIDA
Viatris Inc.
LEIDA 2
Viatris Inc.
Earliest Stage Treatment of Aktinic Keratosis With Imiquimod 3.75% Cream
Medical University of Graz
Toll-like Receptor (TLR) 7 Agonist, Cyclophosphamide, and Radiotherapy for Breast Cancer With Skin Metastases
NYU Langone Health
Epicutaneous Cryoimmunotherapy Combined With Pembrolizumab for Cutaneous Metastatic Breast Cancer
Washington University School of Medicine
Comparison of Treatment of Cervical Intraepithelial Lesions With Imiquimod or LLETZ
University Medical Centre Maribor
PITVIN
Medical University of Graz
Randomized Clinical Trial Evaluating the Efficacy of Topical Imiquimod in High Grade Cervical Intraepithelial Lesions
Barretos Cancer Hospital
Genomic Markers Before and After Treatment of Actinic Keratosis With Imiquimod 3.75% Cream
Icahn School of Medicine at Mount Sinai
Efficacy and Tolerability of Topical LFX453 for External Genital Warts
Novartis
Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis
Teva Pharmaceuticals USA
AdAM
Medical University Innsbruck